Latanoprost in the treatment of glaucoma

Código QR

Latanoprost in the treatment of glaucoma

Albert AlmDepartment of Neuroscience, Ophthalmology, University Hospital, Uppsala, SwedenAbstract: Prostaglandins are approved by the European Glaucoma Society guidelines as first-line treatment for glaucoma. This review focuses on latanoprost, an ester prodrug of prostaglandin (PG) F2α,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Alm A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/4828795329a441158138cffbf848d394
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
por: Pacella F, et al.
Publicado: (2012)

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
por: Andrea Russo, et al.
Publicado: (2009)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi M, et al.
Publicado: (2014)

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
por: Yoshimi Nakamura, et al.
Publicado: (2009)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Antoine Lafuma, et al.
Publicado: (2011)

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study
por: Gutierrez-Diaz E, et al.
Publicado: (2014)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Gregory Katz, et al.
Publicado: (2010)

Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
por: Bhagat P, et al.
Publicado: (2014)

Efficacy and tolerability of a large scale change in regimen from latanoprost to travoprost in glaucoma patients at the Manhattan Veterans Administration Hospital
por: Edmund P Farris
Publicado: (2008)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers JS, et al.
Publicado: (2014)

Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients
por: Makoto Ishikawa, et al.
Publicado: (2009)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Yelda Buyru &Ouml;zkurt, et al.
Publicado: (2009)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
por: Maruyama Y, et al.
Publicado: (2015)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: David A Godfrey, et al.
Publicado: (2009)

Prostaglandin-associated periorbitopathy in latanoprost users
por: Nakakura S, et al.
Publicado: (2014)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue K, et al.
Publicado: (2012)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Michael J Miyashiro, et al.
Publicado: (2010)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction [Corrigendum]
por: Muñoz Negrete FJ, et al.
Publicado: (2017)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Kanamoto T, et al.
Publicado: (2012)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Douglas J Rhee, et al.
Publicado: (2008)

Efficacy and safety of combination therapy with latanoprost after a change in therapeutic regimen from timolol to brinzolamide in Japanese adult patients with primary open-angle glaucoma and ocular hypertension: open, non-randomized 12-week study
por: Shusaku Ishikawa, et al.
Publicado: (2008)

Characteristics of uveitic glaucoma and evaluation of its surgical treatment
por: Shimizu A, et al.
Publicado: (2014)

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
por: Ikeda Y, et al.
Publicado: (2016)

An emerging treatment option for glaucoma: Rho kinase inhibitors
por: Wang SK, et al.
Publicado: (2014)

Mirtogenol&reg; potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects
por: Robert D Steigerwalt Jr, et al.
Publicado: (2010)

Long-term safety and efficacy of selective laser trabeculoplasty as primary therapy for the treatment of pseudoexfoliation glaucoma compared with primary open-angle glaucoma
por: Tarek A Shazly, et al.
Publicado: (2010)

Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost
por: Fechtner RD, et al.
Publicado: (2011)

Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
por: Inoue K, et al.
Publicado: (2013)

Current primary open-angle glaucoma treatments and future directions
por: Beidoe G, et al.
Publicado: (2012)

Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs
por: Jordana K Schmier, et al.
Publicado: (2010)

Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma
por: Marey HM, et al.
Publicado: (2011)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
por: Lanzl I, et al.
Publicado: (2013)

Does the type of treatment have an influence on utility values in a glaucoma population?
por: Paletta Guedes RA, et al.
Publicado: (2015)

Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
por: Canut MI, et al.
Publicado: (2011)

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
por: E Randy Craven, et al.
Publicado: (2010)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
por: Beck DER, et al.
Publicado: (2017)

Trabeculectomy versus Ahmed Glaucoma Valve implantation in neovascular glaucoma
por: Christopher C Shen, et al.
Publicado: (2011)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue K, et al.
Publicado: (2014)

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
por: Inoue K, et al.
Publicado: (2012)

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
por: Ermiş&nbsp;SS
Publicado: (2012)